Member Directory - Pharmaceutical Advisory Board

Chair: Charles Flexner


  • Engage industry in conversations and serve as a key resource to identify barriers in development and to encourage production of LA/ER ARV’s
  • Identify additional experts who can make meaningful contributions to LA/ER topic-specific focus groups, including the generation of educational materials and consensus publications.


Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP).

Conflict of Interest: Dr. Flexner reports receiving consulting income from Gilead Sciences, Merck, ViiV Healthcare, Janssen, and Theratechnologies. He also serves on a scientific advisory board for Navigen Corporation, and serves on a data safety and monitoring board for Advarra. He is a co-inventor on six issued patents related to long-acting drug delivery technology for HIV treatment and prevention.

After his medicinal chemistry PhD and a Marie Curie Fellowship at Utrecht University, Lluis Ballell Pagès joined GlaxoSmithKline in 2005 to lead different preclinical infectious diseases projects and setup the Open Lab..

Conflict of Interest: Receives salary from, and has an ownership interest in, Johnson & Johnson.

Dr. James F. Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and in 2004 became Vice President of Medical Affairs.

Conflict of Interest: None disclosed.

Bill Spreen, Pharm.D, is a Director of Research and Development at ViiV Healthcare and based in Research Triangle Park, North Carolina.

Conflict of Interest: None disclosed.

Kati Vandermeulen, M.SC., is a Senior Director, Compound Development Team Leader at Janssen Infectious Diseases Research and Development in Beerse Belgium.

Conflict of Interest: Has no real or apparent conflicts of interest to report.